KR920703108A - 정제된 cdw52-특이 항체 - Google Patents

정제된 cdw52-특이 항체

Info

Publication number
KR920703108A
KR920703108A KR1019920701427A KR920701427A KR920703108A KR 920703108 A KR920703108 A KR 920703108A KR 1019920701427 A KR1019920701427 A KR 1019920701427A KR 920701427 A KR920701427 A KR 920701427A KR 920703108 A KR920703108 A KR 920703108A
Authority
KR
South Korea
Prior art keywords
antibody
formulation
cdw52
column
protein
Prior art date
Application number
KR1019920701427A
Other languages
English (en)
Other versions
KR960015399B1 (ko
Inventor
얀 니콜라스 라마지 폴
알렌 제프리
Original Assignee
엘. 디. 젠킨스
더 웰컴 파운데이션 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR920703108(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 엘. 디. 젠킨스, 더 웰컴 파운데이션 리미티드 filed Critical 엘. 디. 젠킨스
Publication of KR920703108A publication Critical patent/KR920703108A/ko
Application granted granted Critical
Publication of KR960015399B1 publication Critical patent/KR960015399B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

정제된 CDW52-특이 항체
[도면의 간단한 설명]
제1도(a) '크리플드(crippled)'dhfr 선택/증촉 마커 및 컴패스-1H L-쇄 cDNA에 대한 형질발현 카세트를 함유하는 pLD9 구조를 나타내고 있다. 유전자상에 점선 화살표로 표시된 부분은 약화된 SV40 프로모터이며 점이 찍혀진 부분은 β-엑틴 프로모터를 나타낸다. 폴리 A는 각각 폴리에데닐화 시그널 및 종결 시그널에 해당되는 것이며 ori 부분은 SV40의 복제 오리지을 함유하고 있다. (b) 네오마이신 선택 마커 및 컴패스-1H H-쇄 cDNA에 대한 형질발현 카세트를 하유하는 pNH316구조를 나타내고 있다. MT→부분은 마우스 메탈로 티오나인 프로모터를 나타내는 것이다. 약어로 표시된 제한 효소 부위는 다음과 같이 나타낼 수 있다:-H, HindIII; Bg, BglII, B, BamHT; RI, EcoRI, 제2도는 환원되지 않았거나 환원된 컴패스 1H를 SDS폴리아크릴아미드 겔상에서 전개시킨 것으로서 주된 단일 밴드를 나타내고 있다.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (17)

  1. 크기 배제 크로마토그래피상에서, 비-환원적 조건에서는 단일 피이크를 나타내며 환원적 조건에서는 2개의 주된 피이크를 나타내는 항-CDW52 항체의 정제된 제제.
  2. 제1항에 있어서, 상기 제제는 통상적인 SDS 폴리아크릴아미드 겔 전기영동상에서, 환원되지 않은 샘플이 이용될 경우 하나의 주된 밴드를 나타내며 환원된 샘플이 이용될 경우에는 2개의 주된 밴드를 나타냄을 특징으로 하는 제제.
  3. 제1항 또는 제2항에 있어서, 상기 제제는 역상 HPLC상에서, 비-환원적 조건에서는 단일 피이크를 나타내며 환원적 조건에서는 2개의 주된 피이크를 나타냄을 특징으로 하는 제제.
  4. 특이 활성도가 0.8킬로유니트/mg 이상인 항-CDW52 항체의 정재원 제제.
  5. 숙주 세포 오염물 및/또는 응집체가 거의 함유되지 않은 항-CDW52 항체의 정제된 제제.
  6. 재1항 내지 제5항중 어느 한항에 있어서, 상기 항체는 변형된 항체임을 특징으로 하는 제제.
  7. 제6항에 있어서, 상기 항체는 CDR-그래프트화된 항체임을 특징으로 하는 제제.
  8. a)-CDW52 항체의 수용액을 단백질 A컬럼에 적응시켜 항제가 컬럼상에 흡수되도록 한후 산용액으로 상기 항체를 용출시키는 단계, b) 하전된 입자를 가진 이온-교환 컬럼에 상기 산 용츨액을 적용시켜 항체를 흡수시킨 후 반대로-하천된 이온의 수용액으로 항체를 용출시키는 단계, 및 c) 상기 수용성 용출액을 다공성입자를 갖는 크기 배제 컬럼에 적용시켜, 항체가 아닌 분자들은 다공성 입자내에 머물게 함으로써, 컬럼으로 부터 생성된 선택된 분획에서 목적하는 항체를 수득하는 단계를 포함하는, 항-CDW52 항체의 정제 방법.
  9. 제8항에 있어서, 상기 단백질 A 컬럼은 산성 pH에서 용출됨을 특징으로 하는 방법.
  10. 제8항 또는 제9항에 있어서, 상기 단백질 A 컬럼은 시트르산으로 용출시킴을 특징으로 하는 방법.
  11. 제8항 내지 제10항중 어느 한 항에 있어서, 상기 단백질 A컬럼은 단백질 A세파로즈임을 특징으로 하는 방법.
  12. 제8항에 있어서, 상기 이온-교환 컬럼은 양이은-교환 컬럼임을 특징으로 하는 방법.
  13. 제8항에 있어서, 상기 이온-교환 컬럼은 음이온-교환 컬럼임을 특징으로 하는 방법.
  14. 제1항 내지 제7항중 어느 한 항에 의한 항-CDW52 항체의 정제원 제제 및 생리학적 허용 부형제 또는 담체를 함유하는 제형.
  15. 제1항 내지 제7항중 어느 한 항에 의한 항-CDW52 항제의 정제된 제제를 치료에 사용하는 방법.
  16. T-세포 매개성 질환, 악성 맥관염 급성 류마티스 관절염, 전신성 루피스, 다증 경화증, 숙주에 대한 이식성 질환, 건선, 청소년기 당뇨병, 쇼그렌병, 티로이드성 질환, 근무력증, 이식 거부 또는 천식을 치료하기 의한 면역억제성 약물을 제조하는데 있어서, 제1헝 내지 제7항중 어느 한 항에 의한 항 CDW52 항체의 정제된 제제를 사용하는 방법.
  17. ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019920701427A 1990-10-17 1991-10-17 면역 글로불린의 정제방법 KR960015399B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB909022547A GB9022547D0 (en) 1990-10-17 1990-10-17 Purified immunoglobulin
GB9022547.5 1990-10-17
PCT/GB1991/001816 WO1992007084A1 (en) 1990-10-17 1991-10-17 Purified cdw52-specific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1019920702699A Division KR100193314B1 (ko) 1990-10-17 1992-10-30 정제된 면역 글로불린

Publications (2)

Publication Number Publication Date
KR920703108A true KR920703108A (ko) 1992-12-17
KR960015399B1 KR960015399B1 (ko) 1996-11-13

Family

ID=10683866

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019920701427A KR960015399B1 (ko) 1990-10-17 1991-10-17 면역 글로불린의 정제방법
KR1019920702699A KR100193314B1 (ko) 1990-10-17 1992-10-30 정제된 면역 글로불린

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019920702699A KR100193314B1 (ko) 1990-10-17 1992-10-30 정제된 면역 글로불린

Country Status (29)

Country Link
US (1) US5644036A (ko)
EP (1) EP0504363B2 (ko)
JP (1) JP2638680B2 (ko)
KR (2) KR960015399B1 (ko)
AT (2) ATE162552T1 (ko)
AU (3) AU658926B2 (ko)
BE (1) BE1004226A5 (ko)
BR (1) BR1100358A (ko)
CA (1) CA2069481C (ko)
CH (2) CH681305A5 (ko)
DE (1) DE69128774T3 (ko)
DK (1) DK0504363T4 (ko)
ES (2) ES2112865T5 (ko)
FI (2) FI110003B (ko)
FR (2) FR2668164A1 (ko)
GB (2) GB9022547D0 (ko)
GR (3) GR910100425A (ko)
HU (1) HUT64601A (ko)
IE (1) IE913560A1 (ko)
IL (3) IL99761A0 (ko)
IT (1) IT1250064B (ko)
LU (1) LU88122A1 (ko)
MX (1) MX9203794A (ko)
MY (2) MY136210A (ko)
NZ (2) NZ244114A (ko)
PT (2) PT99248B (ko)
TW (1) TW283710B (ko)
WO (1) WO1992007084A1 (ko)
ZA (2) ZA926191B (ko)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
EP0610447B1 (en) * 1991-10-15 1998-12-16 Btg International Limited CDw52 - SPECIFIC ANTIBODY FOR TREATMENT OF T-CELL MEDIATED INFLAMMATION OF THE JOINTS
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB9300501D0 (en) * 1993-01-09 1993-03-03 Wellcome Found Purification of immunoglobulin
KR19990036028A (ko) † 1995-08-01 1999-05-25 다니엘 케르니 일본뇌염 백신의 공업적인 생산방법 및 이에 의한 백신
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE122004000004I1 (de) * 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
ES2869895T3 (es) 2001-03-09 2021-10-26 Chugai Pharmaceutical Co Ltd Método de purificación de proteínas
EP1404428B1 (en) * 2001-06-05 2006-07-19 Genetics Institute, LLC Methods for purifying highly anionic proteins
GB0220894D0 (en) * 2002-09-09 2002-10-16 Millipore Uk Ltd Method of separation
CA2497364C (en) 2002-09-11 2013-03-19 Chugai Seiyaku Kabushiki Kaisha Protein purification method
CN102174533A (zh) 2002-10-15 2011-09-07 英特塞尔股份公司 编码b族链球菌粘着因子的核酸、b族链球菌的粘着因子和它们的用途
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
JP2007515492A (ja) * 2003-12-22 2007-06-14 ジェンザイム コーポレイション 糖尿病の抗ｃｄ５２抗体治療法
SI1869065T1 (sl) * 2005-03-11 2020-08-31 Wyeth Llc Postopek kromatografije z nizko porazdelitvijo
CN107551270A (zh) 2008-04-11 2018-01-09 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
TWI614267B (zh) 2009-05-13 2018-02-11 建新公司 抗人類ｃｄ５２免疫球蛋白
RU2607022C2 (ru) 2009-05-13 2017-01-10 Джензим Корпорейшн Способы и композиции для лечения волчанки
WO2011090719A2 (en) * 2009-12-29 2011-07-28 Dr. Reddy's Laboratories Ltd. Protein purification by ion exchange
JP5873016B2 (ja) 2010-06-21 2016-03-01 協和発酵キリン株式会社 アミノ酸を利用したタンパク質の精製方法
RU2467783C2 (ru) * 2010-07-30 2012-11-27 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения иммуноглобулина
RU2658504C9 (ru) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
CA2883272A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
RU2714967C2 (ru) 2013-12-27 2020-02-21 Чугаи Сейяку Кабусики Кайся Способ очистки антител с низкой изоэлектрической точкой
TWI808330B (zh) 2014-12-19 2023-07-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
WO2017022651A1 (ja) 2015-07-31 2017-02-09 中外製薬株式会社 アニオン性ポリマーによる抗体を含有する組成物の精製方法
KR102359192B1 (ko) 2016-07-25 2022-02-04 세파론, 인코포레이티드 친화성 크로마토그래피 세정 완충액
SG11201801024XA (en) 2016-08-05 2018-05-30 Chugai Pharmaceutical Co Ltd Therapeutic or preventive compositions for il-8-related diseases
CN113646066B (zh) 2019-03-29 2024-05-31 旭化成医疗株式会社 蛋白质的纯化方法
CN113692420B (zh) 2019-04-08 2023-09-12 旭化成医疗株式会社 用于纯化含蛋白质的溶液的聚酰胺介质及其制造方法
WO2020209318A1 (ja) 2019-04-10 2020-10-15 中外製薬株式会社 Ｆｃ領域改変抗体の精製方法
WO2022260091A1 (ja) 2021-06-10 2022-12-15 三菱ケミカル株式会社 合成吸着剤、抗体の精製方法及び抗体の製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
JP3121823B2 (ja) * 1988-02-12 2001-01-09 ビーティージー・インターナショナル・リミテッド 抗体におけるまたは抗体に関する改良

Also Published As

Publication number Publication date
ES2112865T3 (es) 1998-04-16
AU4521897A (en) 1998-02-12
FR2668164B1 (ko) 1995-04-14
US5644036A (en) 1997-07-01
GB9022547D0 (en) 1990-11-28
JP2638680B2 (ja) 1997-08-06
EP0504363B1 (en) 1998-01-21
FI922380A (fi) 1992-05-25
MY119030A (en) 2005-03-31
AU716402B2 (en) 2000-02-24
GR910100425A (el) 1992-09-25
ZA926191B (en) 1993-04-16
FI922824A (fi) 1992-06-17
PT99248B (pt) 1999-04-30
JPH05504579A (ja) 1993-07-15
DE69128774T2 (de) 1998-06-04
IL102726A (en) 2002-08-14
KR100193314B1 (ko) 1999-06-15
KR960015399B1 (ko) 1996-11-13
CA2069481C (en) 2003-07-29
ES2081742B1 (es) 1996-10-01
ES2081742A1 (es) 1996-03-01
BR1100358A (pt) 2000-03-28
EP0504363A1 (en) 1992-09-23
PT99248A (pt) 1993-06-30
GB9209529D0 (en) 1992-07-01
AU658926B2 (en) 1995-05-04
TW283710B (ko) 1996-08-21
FI110003B (fi) 2002-11-15
MY136210A (en) 2008-08-29
WO1992007084A1 (en) 1992-04-30
HU9202000D0 (en) 1992-10-28
ZA918259B (en) 1993-04-16
AU649078B2 (en) 1994-05-12
PT100988A (pt) 1994-02-28
GR920100471A (el) 1994-06-30
LU88122A1 (fr) 1993-03-15
AU8729491A (en) 1992-05-20
DE69128774T3 (de) 2007-08-16
NZ240247A (en) 1994-03-25
IL102726A0 (en) 1993-01-31
IE913560A1 (en) 1992-04-22
FI922824A0 (fi) 1992-06-17
ATA900791A (de) 1996-06-15
ATE162552T1 (de) 1998-02-15
ES2112865T5 (es) 2007-09-16
ITRM910788A0 (it) 1991-10-16
BE1004226A5 (fr) 1992-10-13
ITRM910788A1 (it) 1993-04-16
FR2677997A1 (fr) 1992-12-24
IT1250064B (it) 1995-03-30
CH681455A5 (ko) 1993-03-31
AU2532192A (en) 1993-02-11
CH681305A5 (ko) 1993-02-26
FI110002B (fi) 2002-11-15
MX9203794A (es) 1992-07-01
CA2069481A1 (en) 1992-04-18
DK0504363T4 (da) 2007-05-29
FI922380A0 (fi) 1992-05-25
GB2253397A (en) 1992-09-09
HUT64601A (en) 1994-01-28
NZ244114A (en) 1995-06-27
PT100988B (pt) 1999-08-31
AU7024294A (en) 1995-01-05
DK0504363T3 (da) 1998-09-21
FR2668164A1 (fr) 1992-04-24
IL99761A0 (en) 1992-08-18
DE69128774D1 (de) 1998-02-26
GR3026588T3 (en) 1998-07-31
EP0504363B2 (en) 2007-02-07

Similar Documents

Publication Publication Date Title
KR920703108A (ko) 정제된 cdw52-특이 항체
Fukano et al. Evaluation of new supports for high-pressure aqueous gel permeation chromatography: TSK-gel SW type columns
Jenik et al. High-performance liquid chromatography of proteins by gel permeation chromatography
Phillips et al. Protein A-coated glass beads: universal support medium for high-performance immunoaffinity chromatography
Linde et al. Non-ideal behaviour of silica-based stationary phases in trifluoroacetic acid—acetonitrile-based reversed-phase high-performance liquid chromatographic separations of insulins and proinsulins
Chiba et al. Affinity purification of human granulocyte macrophage colony-stimulating factor receptor alpha-chain. Demonstration of binding by photoaffinity labeling.
Hake et al. Redox-dependent molecular recognition in proteins: site-directed mutagenesis suggests that cytochrome c oxidation state governs binding and recognition to cytochrome c peroxidase
Madhok et al. Characterization of uterine estrogen receptors by size-exclusion and ion-exchange high-performance liquid chromatography
Ranadive et al. Basic proteins in rat neutrophils that increase vascular permeability
Nice et al. A micropreparative chromatographic strategy for the purification and sequence analysis of murine granulocyte-colony stimulating factor (mG-CSF)
Mistry et al. Separation of bleomycins and their deamido metabolites by high-performance cation-exchange chromatography
Pask-Hughes Characterisation and purification of some glycoproteins by high-performance liqiud chromatography
Kadoya High-performance liquid chromatography of proteins on a ceramic hydroxyapatite with volatile buffers
Namboodiri et al. Purification of sheep pineal N-acetyltransferase
Zelikman et al. Quantitative determination of propranolol in plasma and pharmaceutical preparations by agar‐based cation‐exchange chromatography utilizing the native anion groups in the agaropectin moiety
LUSTENBERGER et al. Purification of Glucocorticoid Receptor from Rabbit Liver by Steroid Affinity Chromatography
Warden et al. Soluble antibody affinity chromatography technique investigated with ultratrace [125I] thyroxine
Wagner Advances in chromatography: Vol. 19, edited by JC Giddings, E. Grushka, J. Cazes and PR Brown, Marcel Dekker, New York, Basel, 1981, XVIII+ 312 pp., price SFr. 98.00, ISBN 0-8247-1246-3.
Weyer et al. Enhancement of the histamine releasing activity of mouse monoclonal anti-human IgE antibody xb6-16 when present in aggregated or complexed forms

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

G160 Decision to publish patent application
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20101029

Year of fee payment: 15

EXPY Expiration of term